The Experts below are selected from a list of 63 Experts worldwide ranked by ideXlab platform

Xin Yuan Guan - One of the best experts on this subject based on the ideXlab platform.

  • characterization of a candidate tumor suppressor gene Uroplakin 1a in esophageal squamous cell carcinoma
    Cancer Research, 2010
    Co-Authors: Kar Lok Kong, Dora L W Kwong, Li Fu, Tim Hon Man Chan, Leilei Chen, Yan Li, Jiong Bi, Xin Yuan Guan
    Abstract:

    Esophageal squamous cell carcinoma (ESCC) is increasing in incidence, but the knowledge of the genetic underpinnings of this disease remains limited. In this study, we identified the tetraspanin cell surface receptor Uroplakin 1a ( UPK1a ) as a candidate tumor suppressor gene (TSG), and we investigated its function and mechanism in ESCC cells. UPK1a downregulation occurred in 68% of primary ESCCs examined, where it was correlated significantly with promoter hypermethylation ( P UPK1a in ESCC cells inhibited cell proliferation, clonogenicity, cell motility, and tumor formation in nude mice. Mechanistic investigations suggested that these effects may be mediated by inhibiting nuclear translocation of β-catenin and inactivation of its downstream targets, including cyclin-D1, c-jun, c-myc , and matrix metalloproteinase 7 ( MMP7 ). Cell cycle arrest elicited by UPK1a at the G 1 -S checkpoint was associated with downregulation of cyclin D1 and cyclin-dependent kinase 4, whereas metastasis suppression was associated with reduction of MMP7 . These findings were consistent with evidence derived from clinical samples, where UPK1a downregulation was correlated with lymph node metastasis ( P = 0.009), stage ( P = 0.015), and overall survival ( P

  • Abstract #4444: Characterization of a novel tumor-suppressor gene UPK1a in esophageal squamous cell carcinoma
    Cancer Research, 2009
    Co-Authors: Kar Lok Kong, Li Fu, Lai-wan Kwong, Xin Yuan Guan
    Abstract:

    AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO Background: Esophageal Squamous Cell Carcinoma (ESCC) has been ranked as the sixth leading cause of cancer death over the world. Like other types of cancer, genetic variation in multiple cancer-related genes is one of the main causes of ESCC. Hence, to have a better understanding of ESCC, it is important to identify these key genes and recognize their roles. Recently, our group performed an Affemetrix cDNA Microarray comparing differentially expressed genes between ESCC tumors and their adjacent nontumorous tissues. Uroplakin 1a (UPK1a) was found to be down-regulated. In this study, the role UPK1a gene in ESCC was characterized. Methods and Results: By reverse transcription-polymerase chain reaction (RT-PCR), 43/50 (86%) primary ESCCs and 8/9 (89%) ESCC cell lines were found no expression of UPK1a which was correlated with promoter hypermethylation. In addition, functional studies such as colony formation in soft agar, cell proliferation assay, foci formation and tumor formation in nude mice showed that UPK1a could suppress the tumorigenicity of ESCC cells in vitro and in vivo. Wound healing assay and cell adhesion assay also suggested that UPK1a inhibit cell mobility and increase cell adhesion ability respectively. Conclusion: Our study indicated that UPK1a has an important suppressive ability in the development and progression which maybe a novel tumor-suppressor gene in ESCC. Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 4444.

Xiaofei Zhang - One of the best experts on this subject based on the ideXlab platform.

  • reduced expression of Uroplakin 1a is associated with the poor prognosis of gastric adenocarcinoma patients
    PLOS ONE, 2014
    Co-Authors: Yan Zheng, Dan Dan Wang, Wei Wang, Chun Yu Huang, Yuan Fang Li, Qi Jing Wang, Shu Qiang Yuan, Shan Shan Jiang, Yong Ming Chen, Xiaofei Zhang
    Abstract:

    Background The aim of this study was to investigate the expression and prognostic significance of Uroplakin1a (UPK1a) in gastric adenocarcinoma patients. Functional studies were also analyzed in vitro. Methodology/Principal Findings Real-time quantitative PCR (RT-qPCR), western blotting, and immunohistochemical (IHC) staining methods were used to analyze the expression of UPK1a in primary gastric adenocarcinoma tissue samples. Compared with matched adjacent non-tumor, the expression of UPK1a in fresh surgical specimens was reduced, which was confirmed by RT-qPCR (P<0.01) and western blotting analysis (P<0.01). The paraffin specimens from a consecutive series of 445 gastric adenocarcinoma patients who underwent surgery between 2003 and 2006 were analyzed by IHC staining. The relationship between UPK1a expression, clinicopathological factors, and survival were evaluated. IHC staining analysis revealed that the reduced expression of UPK1a was observed in 224 cases (50.3%). Additionally, the correlation analysis of clinicopathological factors demonstrated that reduced expression of UPK1a was significantly associated with histological grade (P = 0.022), node metastasis (P<0.001) and tumor node metastasis (TNM) stage (P = 0.008) (7th edition of the International Union Against Cancer (UICC)). Furthermore, Kaplan-Meier survival analysis revealed that the reduced expression of UPK1a was significantly associated with poor prognosis (P = 0.043). Cox hazards model analysis indicated that UPK1a expression was an independent risk factor at the 0.1 level (P = 0.094). The function of UPK1a in cell cycle, migration, and invasion was investigated by overexpressing UPK1a in the MKN45 gastric cancer cell line. The elevated expression of UPK1a cells induced G1 phase arrest and significantly inhibited migration and invasion. Conclusions/Significance The reduced expression of UPK1a might play a role in the progression of gastric cancer. Thus, UPK1a could be a potential favorable biomarker associated with gastric cancer prognosis.

Kar Lok Kong - One of the best experts on this subject based on the ideXlab platform.

  • characterization of a candidate tumor suppressor gene Uroplakin 1a in esophageal squamous cell carcinoma
    Cancer Research, 2010
    Co-Authors: Kar Lok Kong, Dora L W Kwong, Li Fu, Tim Hon Man Chan, Leilei Chen, Yan Li, Jiong Bi, Xin Yuan Guan
    Abstract:

    Esophageal squamous cell carcinoma (ESCC) is increasing in incidence, but the knowledge of the genetic underpinnings of this disease remains limited. In this study, we identified the tetraspanin cell surface receptor Uroplakin 1a ( UPK1a ) as a candidate tumor suppressor gene (TSG), and we investigated its function and mechanism in ESCC cells. UPK1a downregulation occurred in 68% of primary ESCCs examined, where it was correlated significantly with promoter hypermethylation ( P UPK1a in ESCC cells inhibited cell proliferation, clonogenicity, cell motility, and tumor formation in nude mice. Mechanistic investigations suggested that these effects may be mediated by inhibiting nuclear translocation of β-catenin and inactivation of its downstream targets, including cyclin-D1, c-jun, c-myc , and matrix metalloproteinase 7 ( MMP7 ). Cell cycle arrest elicited by UPK1a at the G 1 -S checkpoint was associated with downregulation of cyclin D1 and cyclin-dependent kinase 4, whereas metastasis suppression was associated with reduction of MMP7 . These findings were consistent with evidence derived from clinical samples, where UPK1a downregulation was correlated with lymph node metastasis ( P = 0.009), stage ( P = 0.015), and overall survival ( P

  • Abstract #4444: Characterization of a novel tumor-suppressor gene UPK1a in esophageal squamous cell carcinoma
    Cancer Research, 2009
    Co-Authors: Kar Lok Kong, Li Fu, Lai-wan Kwong, Xin Yuan Guan
    Abstract:

    AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO Background: Esophageal Squamous Cell Carcinoma (ESCC) has been ranked as the sixth leading cause of cancer death over the world. Like other types of cancer, genetic variation in multiple cancer-related genes is one of the main causes of ESCC. Hence, to have a better understanding of ESCC, it is important to identify these key genes and recognize their roles. Recently, our group performed an Affemetrix cDNA Microarray comparing differentially expressed genes between ESCC tumors and their adjacent nontumorous tissues. Uroplakin 1a (UPK1a) was found to be down-regulated. In this study, the role UPK1a gene in ESCC was characterized. Methods and Results: By reverse transcription-polymerase chain reaction (RT-PCR), 43/50 (86%) primary ESCCs and 8/9 (89%) ESCC cell lines were found no expression of UPK1a which was correlated with promoter hypermethylation. In addition, functional studies such as colony formation in soft agar, cell proliferation assay, foci formation and tumor formation in nude mice showed that UPK1a could suppress the tumorigenicity of ESCC cells in vitro and in vivo. Wound healing assay and cell adhesion assay also suggested that UPK1a inhibit cell mobility and increase cell adhesion ability respectively. Conclusion: Our study indicated that UPK1a has an important suppressive ability in the development and progression which maybe a novel tumor-suppressor gene in ESCC. Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 4444.

Yan Zheng - One of the best experts on this subject based on the ideXlab platform.

  • reduced expression of Uroplakin 1a is associated with the poor prognosis of gastric adenocarcinoma patients
    PLOS ONE, 2014
    Co-Authors: Yan Zheng, Dan Dan Wang, Wei Wang, Chun Yu Huang, Yuan Fang Li, Qi Jing Wang, Shu Qiang Yuan, Shan Shan Jiang, Yong Ming Chen, Xiaofei Zhang
    Abstract:

    Background The aim of this study was to investigate the expression and prognostic significance of Uroplakin1a (UPK1a) in gastric adenocarcinoma patients. Functional studies were also analyzed in vitro. Methodology/Principal Findings Real-time quantitative PCR (RT-qPCR), western blotting, and immunohistochemical (IHC) staining methods were used to analyze the expression of UPK1a in primary gastric adenocarcinoma tissue samples. Compared with matched adjacent non-tumor, the expression of UPK1a in fresh surgical specimens was reduced, which was confirmed by RT-qPCR (P<0.01) and western blotting analysis (P<0.01). The paraffin specimens from a consecutive series of 445 gastric adenocarcinoma patients who underwent surgery between 2003 and 2006 were analyzed by IHC staining. The relationship between UPK1a expression, clinicopathological factors, and survival were evaluated. IHC staining analysis revealed that the reduced expression of UPK1a was observed in 224 cases (50.3%). Additionally, the correlation analysis of clinicopathological factors demonstrated that reduced expression of UPK1a was significantly associated with histological grade (P = 0.022), node metastasis (P<0.001) and tumor node metastasis (TNM) stage (P = 0.008) (7th edition of the International Union Against Cancer (UICC)). Furthermore, Kaplan-Meier survival analysis revealed that the reduced expression of UPK1a was significantly associated with poor prognosis (P = 0.043). Cox hazards model analysis indicated that UPK1a expression was an independent risk factor at the 0.1 level (P = 0.094). The function of UPK1a in cell cycle, migration, and invasion was investigated by overexpressing UPK1a in the MKN45 gastric cancer cell line. The elevated expression of UPK1a cells induced G1 phase arrest and significantly inhibited migration and invasion. Conclusions/Significance The reduced expression of UPK1a might play a role in the progression of gastric cancer. Thus, UPK1a could be a potential favorable biomarker associated with gastric cancer prognosis.

  • Reduced expression of Uroplakin 1a is associated with the poor prognosis of gastric adenocarcinoma patients.
    PLOS ONE, 2014
    Co-Authors: Yan Zheng, Dan Dan Wang, Wei Wang, Chun Yu Huang, Yuan Fang Li, Qi Jing Wang, Shu Qiang Yuan, Shan Shan Jiang
    Abstract:

    Background The aim of this study was to investigate the expression and prognostic significance of Uroplakin1a (UPK1a) in gastric adenocarcinoma patients. Functional studies were also analyzed in vitro. Methodology/Principal Findings Real-time quantitative PCR (RT-qPCR), western blotting, and immunohistochemical (IHC) staining methods were used to analyze the expression of UPK1a in primary gastric adenocarcinoma tissue samples. Compared with matched adjacent non-tumor, the expression of UPK1a in fresh surgical specimens was reduced, which was confirmed by RT-qPCR (P

Li Fu - One of the best experts on this subject based on the ideXlab platform.

  • characterization of a candidate tumor suppressor gene Uroplakin 1a in esophageal squamous cell carcinoma
    Cancer Research, 2010
    Co-Authors: Kar Lok Kong, Dora L W Kwong, Li Fu, Tim Hon Man Chan, Leilei Chen, Yan Li, Jiong Bi, Xin Yuan Guan
    Abstract:

    Esophageal squamous cell carcinoma (ESCC) is increasing in incidence, but the knowledge of the genetic underpinnings of this disease remains limited. In this study, we identified the tetraspanin cell surface receptor Uroplakin 1a ( UPK1a ) as a candidate tumor suppressor gene (TSG), and we investigated its function and mechanism in ESCC cells. UPK1a downregulation occurred in 68% of primary ESCCs examined, where it was correlated significantly with promoter hypermethylation ( P UPK1a in ESCC cells inhibited cell proliferation, clonogenicity, cell motility, and tumor formation in nude mice. Mechanistic investigations suggested that these effects may be mediated by inhibiting nuclear translocation of β-catenin and inactivation of its downstream targets, including cyclin-D1, c-jun, c-myc , and matrix metalloproteinase 7 ( MMP7 ). Cell cycle arrest elicited by UPK1a at the G 1 -S checkpoint was associated with downregulation of cyclin D1 and cyclin-dependent kinase 4, whereas metastasis suppression was associated with reduction of MMP7 . These findings were consistent with evidence derived from clinical samples, where UPK1a downregulation was correlated with lymph node metastasis ( P = 0.009), stage ( P = 0.015), and overall survival ( P

  • Abstract #4444: Characterization of a novel tumor-suppressor gene UPK1a in esophageal squamous cell carcinoma
    Cancer Research, 2009
    Co-Authors: Kar Lok Kong, Li Fu, Lai-wan Kwong, Xin Yuan Guan
    Abstract:

    AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO Background: Esophageal Squamous Cell Carcinoma (ESCC) has been ranked as the sixth leading cause of cancer death over the world. Like other types of cancer, genetic variation in multiple cancer-related genes is one of the main causes of ESCC. Hence, to have a better understanding of ESCC, it is important to identify these key genes and recognize their roles. Recently, our group performed an Affemetrix cDNA Microarray comparing differentially expressed genes between ESCC tumors and their adjacent nontumorous tissues. Uroplakin 1a (UPK1a) was found to be down-regulated. In this study, the role UPK1a gene in ESCC was characterized. Methods and Results: By reverse transcription-polymerase chain reaction (RT-PCR), 43/50 (86%) primary ESCCs and 8/9 (89%) ESCC cell lines were found no expression of UPK1a which was correlated with promoter hypermethylation. In addition, functional studies such as colony formation in soft agar, cell proliferation assay, foci formation and tumor formation in nude mice showed that UPK1a could suppress the tumorigenicity of ESCC cells in vitro and in vivo. Wound healing assay and cell adhesion assay also suggested that UPK1a inhibit cell mobility and increase cell adhesion ability respectively. Conclusion: Our study indicated that UPK1a has an important suppressive ability in the development and progression which maybe a novel tumor-suppressor gene in ESCC. Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 4444.